The causes and mechanisms underlying multidrug resistance (MDR) in epilepsy are still elusive and may depend on inadequate drug concentration in crucial brain areas. We studied whether limbic seizures or anticonvulsant drug treatments in rodents enhance the brain expression of the MDR gene (mdr) encoding a permeability glycoprotein (P-gp) involved in MDR to various cancer chemotherapeutic agents. We also investigated whether changes in P-gp levels affect anticonvulsant drug concentrations in the brain. Mdr mRNA measured by RT-PCR increased by 85% on average in the mouse hippocampus 3-24 hr after kainic acid-induced limbic seizures, returning to control levels by 72 hr. Treatment with therapeutic doses of phenytoin or carbamazepine for 7 d did not change mdr mRNA expression in the mouse hippocampus 1-72 hr after the last drug administration. Six hours after seizures, the brain/plasma ratio of phenytoin was reduced by 30% and its extracellular concentration estimated by microdialysis was increased by twofold compared with control mice. Knock-out mice (mdr1a/b Ϫ/Ϫ) lacking P-gp protein showed a 46% increase in phenytoin concentrations in the hippocampus 1 and 4 hr after injection compared with wild-type mice. A significant 23% increase was found in the cerebellum at 1 hr and in the cortex at 4 hr. Carbamazepine concentrations were measurable in the hippocampus at 3 hr in mdr1a/b Ϫ/Ϫ mice, whereas they were undetectable at the same time interval in wild-type mice. In rats having spontaneous seizures 3 months after electrically induced status epilepticus, mdr1 mRNA levels were enhanced by 1.8-fold and fivefold on average in the hippocampus and entorhinal cortex, respectively. Thus, changes in P-gp mRNA levels occur in limbic areas after both acute and chronic epileptic activity. P-gp alterations significantly affect antiepileptic drugs concentrations in the brain, suggesting that seizure-induced mdr mRNA expression contributes to MDR in epilepsy.
Approximately 30% of patients with epilepsy develop intractable seizures [i.e., seizures persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs (AEDs)] (Collaborative Group for the Study of Epilepsy, 1992; Cockerell et al., 1995) . The mechanisms underlying multidrug resistance (MDR) in epilepsy are still elusive. Some risk factors have been identified in patients, (i.e., time of onset of epilepsy, type and etiology of seizures, and number of seizures before the start of the treatment) (Reynolds, 1987; Hauser and Hesdorffer, 1990 ; Collaborative Group for the Study of Epilepsy, 1992); however, they do not provide a convincing explanation of why and how a subset of patients is drug-refractory. It is likely that MDR is a multifactorial phenomenon that includes both pharmacodynamic and pharmacokinetic mechanisms. It has been hypothesized that the changes in the electrical and synaptic properties of neurons induced by epileptogenesis in specific brain areas make the epileptic tissue less susceptible to the action of AEDs (Sashihara et al., 1992; Lombardo et al., 1996) . Etiological factors in the embryonic period interfering with the differentiation and neuronal migration of neurons (i.e., cerebral dysplasia) are often associated with pharmacoresistant forms of epilepsy (Spreafico et al., 1998) . MDR in epilepsy may also depend on an inadequate intraparenchimal AED concentration. This may occur if AEDs are actively extruded from the brain after their entry through the vascular bed. In this regard, MDR to various chemotherapeutic agents in mammalian tumor cells has been suggested to depend on the increased expression and activity of a membrane-located permeability glycoprotein (P-gp) (Juliano and Ling, 1998) extruding with an energy-dependent mechanism a wide range of structurally unrelated, amphiphilic or hydrophobic drugs from the cell (Endicott and Ling, 1989) .
Using epithelial cell lines expressing P-gp and in vivo microdialysis experiments in rats, it has been shown that phenytoin and carbamazepine are substrates of this pump (Tishler et al., 1995; Schinkel et al., 1996; Potschka et al., 2001) , and that other AEDs have a structure compatible with being substrates of the P-gp (Morrow and Cohen, 1988) . P-gps are encoded by small gene families, MDR1 and MDR3 in humans and mdr1a, mdr1b, and mdr2 in rodents. MDR1, mdr1a, and mdr1b cDNA confer MDR. P-gps encoded by MDR1 and mdr1a and mdr1b genes are highly concentrated in capillary blood vessels of the brain and in secretory epithelia of peripheral organs (Thiebaut et al., 1987; Croop et al., 1989; Tishler et al., 1995) . The lack of P-gp in mdr1a/b Ϫ/Ϫ mice affects drug transport into the brain more than in any other peripheral organ (Schinkel et al., 1994) . The normal function of this transporter appears to involve steroid secretion, transepithelial and transendothelial transport of toxic xenobiotics, or certain endogenous metabolites and cytokines (Gottesman and Pastan, 1993) .
It has been reported recently that the levels of mRNA of the MDR1 gene encoding P-gp were enhanced more than ten times in brain tissue surgically removed from patients with pharmacoresistant epilepsy (Tishler et al., 1995) . In addition, enhanced immunostaining in astrocytes and in neurons was found in human brains from drug-refractory epileptic patients with malformations of cortical development (Sisodiya et al., 1999 (Sisodiya et al., , 2001 or tuberous sclerosis (Lazarowski et al., 1999) . One report has also shown increased immunoreactivity in glia 1 d to 2 weeks after intracerebral kainate injection in rats (Zhang et al., 1999) .
Seizures of particular intensity and duration may change the expression of proteins both in neurons and glia in specific brain areas and alter the permeability properties of the blood-brain barrier (Nitsch et al., 1986) . Moreover, chronic treatment with drugs acting in the CNS can modify the density and/or affinity of the respective receptor proteins in the brain. Although P-gp cannot be regarded as a classical receptor protein, the transported drugs have specific binding sites on its domains (Endicott and Ling, 1989; Gottesman and Pastan, 1993; Martin et al., 2000) .
Thus, this study addressed three major points: (1) whether mrd1 mRNA expression in rodent brain was enhanced by acute seizures and chronic epileptic activity, (2) whether mdr1 mRNA expression in rodent brain was enhanced by repetitive AED treatment, and (3) whether P-gp levels effectively influence AED concentrations in the brain. To this aim, we used transgenic mice lacking P-gp and rodent brain tissue overexpressing this transport pump.
Our results suggest that upregulation of P-gp in the brain after seizures may contribute to MDR in epilepsy.
MATERIALS AND METHODS Animals
C57BL /6 male adult mice (25 gm) and Sprague Dawley male rats (250 -350 gm) (Charles River, C alco, Italy) were used. The mdr1a/b Ϫ/Ϫ mice and their wild-type littermates were purchased from Taconic (Germantown, MD). These are homozygous mice lacking both isoforms of the mdr1 gene; therefore, these mice are deficient in P-gp (Schinkel et al., 1994) .
The animals were housed at constant temperature (21 Ϯ 1°C) and relative humidity (60%) under a fixed 12 hr light /dark cycle. Food and water were available ad libitum. Procedures involving mice or rats and their care were conducted in conformity with institutional guidelines that were in compliance with national (4 Decreto Legislativo 116, Gazzetta Ufficiale, suppl 40, 18-2-1992) 
Seizure induction in mice
Limbic seizures were induced in C57BL /6 mice by intraperitoneal injection of 30 mg / kg kainic acid (Tocris Cookson, Bristol, UK). Seizures were observed behaviorally, and only mice with recurrent stage 4 -5 seizures (Racine, 1972) for at least 90 min (observation period) were used for subsequent biochemical assessments.
Mice were decapitated at various times (3-72 hr) after seizure onset (17.2 Ϯ 0.9 min) (n ϭ 5 mice each experimental group). Various brain areas (hippocampus, cortex, and cerebellum) were used for RT-PCR analysis of mdr1 mRNA.
Self-sustained limbic status epilepticus in rats
For hippocampal EEG recording and angular bundle stimulation, two pairs of insulated stainless steel electrodes were implanted under electrophysiological control. The procedures of electrode implantation, seizure induction, and continuous EEG measurements using seizure detection software have been described previously (Gorter et al., 2001) . Briefly, the rats underwent a series of tetanic stimulations (50 Hz) of the hippocampus in the form of a train of pulses every 13 sec. Each train consisting of biphasic pulses (pulse duration, 0.5 msec; maximal intensity, 500 A) had a duration of 10 sec. Stimulation was stopped when the rats displayed sustained forelimb clonus and salivation for minutes (within 60 min from beginning of stimulation). Usually, immediately after the termination of the stimulation, periodic epileptiform discharges (PEDs) at a frequency of 1-2 Hz were evident in the hippocampal EEG. PEDs continued to be displayed for at least 4 hr after the end of tetanic stimulation [defined as status epilepticus (SE)]. We did not include a definition of the occurrence of behavioral seizures in SE, because such seizures could have a variety of forms of appearance, whereas the EEG criterion was more reliable. Rats in which the electrical stimulation did not induce SE were defined as belonging to the non-SE group. SE rats (n ϭ 6) and non-SE rats (n ϭ 5) were placed under continuous EEG monitoring for 24 hr/d for as long as 3-4 months as described previously (Gorter et al., 2001) .
Sham-operated control rats (n ϭ 6) were implanted with electrodes and handled in the same way but were not stimulated. After EEG recording, rats were disconnected and decapitated.
RT-PCR analysis of mdr mRNA was performed on samples of the stimulated hippocampus and the contralateral entorhinal cortex of sham (n ϭ 6) and post-SE (n ϭ 6) rats 3 months after electrical stimulation. One group of rats that did not develop SE but experienced only several clonic seizures during stimulation (non-SE rats; n ϭ 5) was also evaluated 3 months after stimulation.
AED treatment
Phenytoin and carbamazepine were given intraperitoneally in mice at 30 and 15 mg / kg, respectively (dissolved in saline alkalinized with 0.1N NaOH). These doses are within the range of those effective in rodent models of epilepsy (Frey and Janz, 1985) . AEDs were administered twice a day 8 hr apart for 7 d. E xperimental and vehicle-injected mice (n ϭ 5 for each group) were killed 1-72 hr after the last drug administration for AED or mRNA measurements. The 1 hr time-point was chosen to measure mdr1 mRNA when maximal concentrations of the AEDs were reached in the tissue. AED treatment was stopped at the seventh day of administration because mice showed signs of toxicity if the treatment was prolonged f urther (i.e., decreased locomotion, drowsiness, and loss of weight).
mdr1 mRNA measurements
Total RNA was isolated from mouse or rat tissue according to the acid guanidinium-phenol-chloroform method (Bendotti et al., 1991) . After the extraction, 1 g of total RNA was used as a substrate for singlestranded cDNA synthesis using murine leukemia virus reverse transcriptase (50 U/l; PerkinElmer, Emery ville, CA), random hexamers (2.5 M), and deoxyN TP mix (1.25 mM each) in a final volume of 20 l. The mixture was incubated at room temperature for 10 min, at 42°C for 15 min, at 99°C for 5 min, and at 5°C for 5 min. An aliquot (10 l) of the cDNA synthesis mixture was used for PCR to amplif y the cDNAs encoding for ␤-actin (used as internal control for cDNA added to the PCR) and rodent mdr1. The PCR primers used are shown in Table 1 .
Primer extension was performed with 1.25 U of AmpliTaq DNA polymerase (PerkinElmer) in a final volume of 50 l. Denaturing, annealing, and extension steps were performed at 95°C for 1 min, at 60°C for 1 min, and at 72°C for 1 min in a thermocycler (Omn-E; Hybaid, Ashford, UK). After the PCR, one-half of the product was loaded onto a 1% agarose gel stained with ethidium bromide and the resulting bands were quantitated by densitometry using an Image Master video documentation system (Pharmacia Biotech, Sunny vale, CA) and ImageQuant version 1.2 software (Molecular Dynamics, Sunny vale, CA). Optical densities of all mdr1 bands were normalized to the corresponding ␤-actin levels ( Fig. 1) .
Microdialysis experiment
C57BL /6 mice were anesthetized with Equithesin (1% phenobarbital /4% chloral hydrate; 3.5 ml / kg, i.p.; Sigma, St. L ouis, MO) and placed in a stereotaxic apparatus (David Kopf Instruments, T ujunga, CA). During surgery, the mouse skull was exposed and two holes were made at the level of the dorsal hippocampus. A vertical dialysis probe with a 1 mm exchanging membrane (C M A10; C arnegie Medicine AB, Stockholm, Sweden) was positioned on each side to reach the dorsal hippocampus (coordinates from bregma: anteroposterior, Ϫ1.9; lateral, Ϯ1.5; Ϫ1.5 below the dura). Each probe was perf used with artificial C SF at the constant rate of 1 l /min. The perf usate was discarded during the first 30 min, and then three consecutive 30 min samples were collected, one before (blank) and two after phenytoin injection (30 mg / kg, i.p.) to cover the time at which phenytoin concentrations were maximal in the tissue. This protocol was applied to mice 6 hr after receiving an intraperitoneal injection of saline (n ϭ 5) or 30 mg / kg kainic acid (n ϭ 5). This was the time of maximal mdr1 mRNA expression after kainate injection.
At the end of the dialysis experiment, the fibers were withdrawn from the tissue and the mice were decapitated. Both hippocampi were rapidly dissected out, and plasma was obtained from the blood for subsequent AED measurements (see below).
AED measurements
Brain tissue and plasma. C arbamazepine and its main metabolite 10,11-carbamazepine-epoxide and phenytoin were determined in plasma and various brain areas by HPLC, after a liquid-liquid extraction procedure. Briefly, carbamazepine was measured in plasma samples (0.2 ml) extracted twice with ethyl acetate (1 ml) after adding the internal standard (mephenytoin) and 0.2 ml of 0.5 M phosphate buffer, pH 7.4. Phenytoin was measured in 0.2 ml of plasma extracted with chloroform (2 ml) after adding mephenytoin and 30 l of acetic acid. After centrif ugation, the organic phases were separated and evaporated to dryness. The residues were dissolved in the mobile phase (see below) and analyzed by HPLC with UV detection (210 nm). Brain areas were homogenized (10 ml /gm) in methanol / water (60:40, v/ v) and processed as described for plasma.
Separation was done on a Spheri-5 RP18 column (PerkinElmer) (25 cm ϫ 4.6 mm inner diameter; 5 m particle size) at room temperature. The mobile phase was 0.01 M phosphate buffer, pH 7.4:CH3C N:CH3OH: n-butanol (70:15:14:1, v/ v), delivered at a flow rate of 1.2 ml /min (Liu et al., 1993) .
The retention times were ϳ32.5 and 13.7 min for carbamazepine and its metabolite, respectively. The retention time was 31 min for phenytoin, 10.3 min for its metabolite 5-(4-hydroxyphenyl)-5-phenythoin, and 17 min for mephenytoin.
Standard curves were prepared daily by adding known concentrations of carbamazepine or phenytoin and their main metabolites to plasma or brain tissue from untreated mice. Linear regression analyses revealed correlation coefficients invariably exceeding 0.998 for all compounds. For carbamazepine and 10,11-carbamazepine-epoxide, the lower point of the calibration graph was 250 ng /ml, using 0.2 ml of plasma or brain homogenate. The lower point of the graph was 500 ng /ml for phenytoin and 250 ng /ml for its metabolite using the same volume of tissues. At these concentrations, coefficients of variation for the precision of the assay were Ͻ15%, whereas higher concentrations gave values between 2 and 10% for all compounds in all tissues.
HPLC-mass spectrometr y/mass spectrometr y anal ysis of phenytoin in brain dial ysate. Analysis of phenytoin was performed with an API 3000 triple quadrupole instrument (Applied Biosystems-Sciex, Thornhill, Ontario, C anada), interfaced with two Series 200 micro LC pumps (PerkinElmer) through a standard T urboIonSpray source (PerkinElmer). HPLC conditions were as follows: column: L una C18, 3 m, 2 ϫ 50 mm (Phenomenex, Chemtek Analitica, Bologna, Italy); flow: 0.2 ml /min; eluent A: 0.01% formic acid in water; eluent B: acetonitrile; gradient: from 20% B to 70% B in 5 min; loop: 20 l. The HPLC effluent was directed to the mass spectrometry (MS) instrument through a splitting T connection that allowed reduction of the flow into the ion source to its optimal value (40 l /min). MS conditions were as follows: source, T urboIonSpray in negative ion mode and with heater gas at 320°C; ion spray voltage, Ϫ4400 V; orifice voltage, Ϫ56 V; ring voltage, Ϫ240 V; collision cell gas, nitrogen at a pressure of 2.6 ϫ 10 Ϫ5 torr; collision energy, 30 electron volt (eV) (phenytoin) and 22 eV (mephenytoin, internal standard). Quantitative analysis of phenytoin was done by multiple-reaction monitoring (MRM), measuring the fragmentation product (m /z 102) of the deprotonated pseudo-molecular ion (m /z 251). Mephenytoin was used as internal standard, by measuring a similar MRM transition (m /z 217 3 m /z 188). C alibration curves (typical r Ն 0.990) were obtained by injecting standard solutions containing variable amounts of phenytoin (5-100 ng /ml) and a fixed amount of mephenytoin (100 ng /ml).
Dialysate samples were pooled from both hippocampi of each mouse and 20 l was spiked with 2 ng of mephenytoin in 30 l of water/ acetonitrile 2:1 and transferred to the HPLC autosampler vials (PerkinElmer Series 200) for HPLC -MRM injections.
Statistical analysis of data
Data are means Ϯ SE (n ϭ number of animals in each group). The effects of treatments were analyzed by one-way ANOVA followed by T ukey's or Mann -Whitney's test for unconfounded means. Figure 1 shows a representative gel of RT-PCR amplification products stained with ethidium bromide from the hippocampi of control and experimental mice 24 hr after kainic acid injection. The increase in the level of mdr1 mRNA is evident in the animal treated with kainic acid (Fig. 1, lane 2) compared with the control mouse (Fig. 1, lane 1) .
RESULTS
To investigate whether expression of mdr1 mRNA in the brain was affected by acute seizure activity, we performed a detailed time course of changes after kainic acid injection in mice using RT-PCR (Fig. 2) .
Between 3 and 24 hr after the onset of limbic seizures, the hippocampal levels of mdr1 mRNA were increased by 85% on average ( p Ͻ 0.01; n ϭ 5 mice for each group), returning to control levels by 72 hr. Mdr1 mRNA was not significantly modified in the cerebellum or cortex 6 hr after seizures (data not shown). No changes in mrp1 mRNA, a different MDR-associated protein (Zaman et al., 1994) , were found in the same brain tissues 3 and 24 hr after seizures (data not shown). We subsequently studied whether repetitive AED treatment induces mdr1 mRNA in the brain. Figure 3 shows that transcript levels did not change in the hippocampus 1-72 hr after the last administration of 30 mg/kg phenytoin or 1-6 hr after 15 mg/kg carbamazepine (each drug given for 7 consecutive days).
To monitor the AED levels in the brain at the time of mdr1 mRNA analysis, we measured their concentrations in the hippocampus and plasma in a different group of mice (n ϭ 4 each group) treated with the AEDs for 7 consecutive days and killed 1-72 hr after the last administration. Table 2 shows that phenytoin concentrations in the hippocampus and plasma decreased in a time-dependent manner, and that the drug was not detectable in brain or plasma after 72 hr. Carbamazepine and 10,11-carbamazepine-epoxide concentrations in the hippocampus were measurable at 1 hr after the last dosing, whereas both drugs were not detected in tissue or in plasma at 6 hr.
We then studied whether changes in P-gp levels resulted in modifications in AED concentrations in the brain using two approaches: we used knock-out mice carrying disruption of the endogenous genes mdr1a and mdr1b leading to deficiency of both P-gps (Schinkel et al., 1994) or mice in which mdr1 mRNA was overexpressed by seizures. Table 3 shows phenytoin or carbamazepine and its metabolite concentrations in the hippocampus and plasma of knock-out mice lacking P-gp. Compared with their wild-type littermates, Ϫ/Ϫ mice showed significantly higher concentrations of phenytoin in the hippocampus (ϩ46% on average) both 1 and 4 hr after 30 mg/kg phenytoin. Plasma levels were not modified; thus the ratio between brain tissue and plasma was increased 1.6-fold in Ϫ/Ϫ mice ( p Ͻ 0.01).
The brain/plasma ratio was significantly increased at 1 hr after treatment in the cerebellum (wild-type, 1.4 Ϯ 0.05; Ϫ/Ϫ, 2.0 Ϯ 0.2; p Ͻ 0.01) and at 4 hr after treatment in the cortex (wild-type, 1.2 Ϯ 0.04; Ϫ/Ϫ, 1.5 Ϯ 0.06; p Ͻ 0.01). Phenytoin metabolite was below the limits of quantification of the analytical procedure both in brain and plasma.
Carbamazepine concentrations did not differ in the hippocampus of Ϫ/Ϫ mice compared with wild-type mice 1 hr after treatment. At 3 hr, carbamazepine levels were not detectable in wild-type mice but were 2.4-and 1.6-fold above the lower point of the calibration curve in the hippocampus and plasma of Ϫ/Ϫ mice. 10,11-Carbamazepine-epoxide levels were significantly elevated in brain tissue of Ϫ/Ϫ mice versus wild-type mice at both 1 and 3 hr ( p Ͻ 0.01).
mRNA overexpression observed in the hippocampus 6 hr after seizures resulted in a 30% decrease ( p Ͻ 0.05) in the brain/ b Hippocampus-to-plasma concentration ratio. ND, Not detectable. The AED levels are higher than those reported in Table 4 , as expected after a chronic treatment protocol.
plasma ratio of phenytoin and in a 2.3-fold increase in the extracellular drug concentration ( p Ͻ 0.01) compared with naive mice (Table 4) , as estimated by brain microdialysis. Finally, to study whether mdr1 expression was increased in brain tissue of chronically epileptic animals, we used rats that had developed self-sustained limbic SE after electrical stimulation of the hippocampus, representing a well established model of spontaneous seizures in rodents (Fountain et al., 1998; Gorter et al., 2001) . Figure 4 depicts the increase in the level of mdr1 mRNA in the stimulated hippocampus and contralateral entorhinal cortex of rats 3 months after induction of SE. The entorhinal cortex was chosen because it is a limbic area that is significantly recruited in seizure generalization in this model (Fountain et al., 1998) .
The average duration of SE in stimulated rats was 10.5 Ϯ 2.4 hr (n ϭ 6) as assessed by continuous on-line EEG recording after electrical stimulation as described previously in detail (Gorter et al., 2001) . The average number of spontaneous seizures observed during the last week of recording before killing was 8.0 Ϯ 1.6 seizures/d. Mdr1 mRNA levels were significantly increased in both regions (1.8-fold in the hippocampus and fivefold on average in the entorhinal cortex; p Ͻ 0.01). No significant changes in mdr1 mRNA levels were found in non-SE rats (data not shown). The electrical stimulation did not induce SE but only short-lasting seizure activity in these rats (0.1 Ϯ 0.05 hr; n ϭ 5), and these same rats rarely show late spontaneous seizures (for more details, see Gorter et al., 2001 ). 
Data are means Ϯ SE of five animals. mdr1a/b Ϫ/Ϫ mice are C57BL/6 mice lacking both isoforms of P-gp. a The tissue concentrations of its metabolite 5-(4-hydroxyphenyl)-5-phenytoin were below the limits of quantification of the analytical procedure. Data are the means Ϯ SE (n ϭ 5 mice for each group). Mice were injected intraperitoneally with 30 mg/kg kainic acid or its vehicle and killed 6 hr later when P-gp overexpression was maximal (Fig. 2 ). *p Ͻ 0.05; **p Ͻ 0.01 versus controls by Mann-Whitney test.
DISCUSSION
This study shows that limbic seizures that are relatively resistant to AED treatment (Reynolds, 1987; Hauser and Hesdorffer, 1990; Loscher, 1997) induce mdr1 mRNA to a large extent in limbic areas. This increase appears to be specific, because mrp1, a different P-gp involved in MDR (Zaman et al., 1994) , was unchanged. Mdr1 mRNA overexpression in kainate-injected mice was transient but outlasted their acute seizures by several hours, suggesting that ongoing epileptic activity may result in sustained increase of this protein.
This was confirmed by measuring mdr1 mRNA levels in epileptic tissue from spontaneously epileptic rats. Thus, in these animals mdr1 mRNA expression was enhanced 3 months after the acute SE both in the hippocampus, where seizures were initially triggered, and in the entorhinal cortex, an area involved in seizure generalization and spread (Fountain et al., 1998) . These findings clearly indicate that spontaneously recurring limbic seizures are associated with elevated levels of mRNA of this transport protein.
Recent studies have indeed shown overexpression of MDR1 in the epileptic focus obtained at surgery from drug-refractory epileptic patients (Tishler et al., 1995) . P-gp is membrane bound and highly expressed in secretory epithelia in a variety of peripheral tissues (Thiebaut et al., 1987) , and it is expressed at relatively low levels in normal brain by endothelial cells at the blood-brain barrier (Cordon-Cardo et al., 1989) . Specific immunoreactivity was found on astrocytic-like foot processes around blood vessels (Tishler et al., 1995; Golden and Pardridge, 1999; Sisodiya et al., 1999 Sisodiya et al., , 2001 .
Increased P-gp has been observed in various pathological conditions associated with drug-resistant epilepsy in humans. Thus, P-gp immunoreactive glia were found in brain tissue from epilepsy patients with malformations of cortical development (Sisodiya et al., 1999) or in tuber cells in tuberous sclerosis (Lazarowski et al., 1999) . Both endothelial and glial cells (astrocytes) appear to overexpress the pump in human epileptic and rat brain tissue (Sisodiya et al., 1999; Zhang and Lee, 1999; Rizzi et al., 2001) .
The evidence that both phenytoin and carbamazepine accumulate in the brains of knock-out mice lacking the mdr1 gene to a larger extent than in wild-type mice indicates that these AEDs are indeed substrates of this pump. Accordingly, Schinkel et al. (1996) and Tishler et al. (1995) have reported previously that phenytoin is transported both by human MDR1 and by rodent mdr1a P-gp in transfected cells. Our findings are in line with recent evidence by Potschka et al. (2001) , who demonstrated in vivo that carbamazepine is a substrate of P-gp using brain microdialysis in rodents and blockers of P-gp function. Moreover, mice lacking one isoform of this transport protein (mdr1a Ϫ/Ϫ) accumulate significantly less carbamazepine and various AEDs in their brain compared with wild-type littermates (Sills and Kwan, 2001) .
In contrast, Owen et al. (2001) did not find changes in carbamazepine levels in the brains of mdr1a/b Ϫ/Ϫ mice versus wild-type mice. However, these authors measured levels of the AEDs in the entire brain, whereas we have shown here that the extent of changes in AED levels is area-specific. Moreover the time points at which they measured carbamazepine (1 and 4 hr) may not be optimal to reveal the differences using whole-brain tissue (see present data). Schinkel et al. (1994) showed that the most pronounced pharmacological effect of mdr1a inactivation was in the brain, indicating that P-gp plays an important transporter role in the bloodbrain barrier and possibly in brain tissue as well.
Resistance to treatment can be an intrinsic feature of the disease itself or can be acquired after treatment with AEDs. We therefore studied whether chronic AED treatment may per se affect the expression of the pump. At therapeutic doses, both phenytoin and carbamazepine appear to be ineffective on the levels of mdr1 mRNA, thus suggesting that seizure activity is likely to be the main determinant in enhancing P-gp gene expression in epilepsy rather than AED treatment. P-gp acts as an ATP-dependent drug efflux system in the cells. The overall P-gp activity controlling drug transport is dependent on two parameters: (1) the level of expression of the mdr1 gene determining the amount of protein that is synthesized in the cells (Endicott and Ling, 1989) and (2) the functionality of the mdr1-encoded P-gp, which determines which substrates are recognized and transported (Gottesman and Pastan, 1993) . Sensitivity of tumor cells toward chemotherapy often correlates inversely with increased mdr1 expression (Goldstein et al., 1989; Pirker et al., 1991) .
To assess whether brain P-gp overexpression was functionally relevant for influencing local AED concentrations, we studied the whole tissue as well as the extracellular concentration of phenytoin at the time of maximal mdr1 mRNA increase after acute seizures in mice. The brain/plasma ratio of phenytoin was drastically reduced and its extracellular disposition was increased in mice treated previously with kainic acid.
This evidence suggests that the function of the pump is modified by seizures as a reflection of its enhanced synthesis. Increased P-gp would impair drug access to its target sites on neurons at two consecutive steps: (1) at the level of the endothelial cells of the brain capillaries thus, leading to decreased tissue concentrations (Munari et al., 1994) , and (2) at the level of the astrocytic endfoot processes ensheathing brain capillaries and surrounding neurons. This would determine a dynamic net flux of the drug from the neurons back to the blood stream and may result in less drug being available for interactions with its receptor or acceptor sites in neurons. Increased drug in dialysate, vis-à-vis with decreased whole-tissue levels, likely reflects a reservoir-like effect caused by its enhanced extrusion from brain parenchyma when the P-gp is functionally activated.
Epileptic activity may enhance P-gp as a defensive mechanism to extrude toxic compounds produced within the brain or entering the brain from the blood (Nitsch et al., 1986) . This induction may occur to a larger extent in predisposed individuals [i.e., with defective mechanisms controlling MDR1 gene expression (Gottesman and Pastan, 1993) ]. In this regard, a functional polymorphism of the human MDR gene has been found to correlate with the expression level and function of this protein (Hoffmeyer et al., 2000) .
If the P-gp plays a significant role as one of the factors contributing to MDR, then it will be important to develop new AEDs that are not substrates of this pump and/or exploit pharmacological treatments aimed at inhibiting its function (Rivoltini et al., 1990; Lemaire et al., 1996; Desrayaud et al., 1998; Dantzig et al., 2001) to ameliorate the efficacy of AEDs in patients refractory to current therapies. In this regard, it is interesting to note that kainate seizures did not affect mdr1 mRNA in the cerebellum, a brain area not directly involved in epileptic activity in this model but known to mediate many side-effects of AEDs. Thus, the area-specific increase in P-gp raises the possibility that blockers of
